1/3
09:19 am
cycc
David Lazar acquires Cyclacel Pharmaceuticals preferred stock, becomes interim CEO; stock jumps [Seeking Alpha]
High
Report
David Lazar acquires Cyclacel Pharmaceuticals preferred stock, becomes interim CEO; stock jumps [Seeking Alpha]
1/3
09:01 am
cycc
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
High
Report
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
12/25
02:02 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/17
02:03 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/9
02:02 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/5
04:13 pm
cycc
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs [Yahoo! Finance]
Low
Report
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs [Yahoo! Finance]
12/5
04:05 pm
cycc
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
High
Report
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
12/1
03:05 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/23
03:33 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/15
05:29 am
cycc
Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations [Yahoo! Finance]
Medium
Report
Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations [Yahoo! Finance]
11/15
03:07 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/14
04:27 pm
cycc
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds [Yahoo! Finance]
Medium
Report
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds [Yahoo! Finance]
11/14
04:15 pm
cycc
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
Low
Report
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
11/13
12:30 pm
cycc
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds [Yahoo! Finance]
Medium
Report
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds [Yahoo! Finance]
11/13
12:22 pm
cycc
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Low
Report
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
11/12
08:04 pm
cycc
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss [Yahoo! Finance]
High
Report
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss [Yahoo! Finance]
11/12
04:50 pm
cycc
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update [Yahoo! Finance]
11/12
04:45 pm
cycc
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
High
Report
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
11/7
02:04 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/30
02:07 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/25
06:43 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) was downgraded by analysts at Roth Capital from a "strong-buy" rating to a "hold" rating.
Medium
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) was downgraded by analysts at Roth Capital from a "strong-buy" rating to a "hold" rating.
10/24
09:15 am
cycc
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
High
Report
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
10/23
09:20 am
cycc
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium [Yahoo! Finance]
High
Report
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium [Yahoo! Finance]
10/23
09:15 am
cycc
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
High
Report
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
10/22
02:02 am
cycc
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.